ClinicalTrials.gg
RecruitingNCT05991817Updated Nov 20, 2025

Sevoflurane General Anesthetic and Spatial Memory in Humans

An observational study in Spatial Memory Disorder, sponsored by University of Chile. Recruiting at 2 sites in Chile. Open to participants aged 30 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-11-20.

Sponsored by University of Chile · Observational

From the registry’s dates

  • Primary completion was expected by Nov 2025, 11 months ago, but the record still lists the study as recruiting.
  • Started Aug 2023; still recruiting 3 years 2 months later.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
22
Ages
30 Years to 50 Years
Sex
All
01

Study summary

The goal of this observational study is to learn about the effect of general anesthetic on spatial memory in adults who will undergo to an elective surgery. The main question it aims to answer is:

  • A surgical event under general anesthesia with sevoflurane transiently impairs spatial memory in humans and induces an increase in inflammatory cytokines.

Participants will perform a virtual maze test and plasma samples will be taken before and after surgery.

Read the detailed description

Postoperative cognitive dysfunction (POCD) occurs after a surgical event under general anesthesia and is characterized by a decline in one or more cognitive functions. POCD is defined as delayed neurocognitive recovery if it takes place within the first 30 days, if it exceeds that time it is known as postoperative neurocognitive disorder. The pathogenesis of this dysfunction is not entirely clear. However, the most accepted hypothesis would be neuroinflammatory, which would take place due to the contribution of inflammatory factors typical of surgical trauma under general anesthesia, with anesthetics such as sevoflurane. Consequently, one of the areas most susceptible to this inflammatory environment would be the hippocampus, a structure responsible for learning and memory. Spatial memory is responsible for encoding and retrieving information about the environment and spatial orientation. To confirm this hypothesis, an elective laparoscopic cholecystectomy under general anesthesia with sevoflurane, plasma measurement of cytokines interleukin-1beta and tumor necrosis factor-alpha and virtual navigation tests will be performed before and after an elective laparoscopic cholecystectomy under general anesthesia with sevoflurane, in order to establish a correlation between the inflammatory component and performance in the virtual navigation test. The above will allow us to elucidate the possible occurrence of a delayed neurocognitive recovery related to spatial memory in middle-aged individuals, providing new background related to an age group that has been little studied, with a non-minor incidence (30%), where the evident concern arises for being a population exposed to activities or environments of greater risk, linked to work, sport, driving, among others. This finding will guide the doctor and the patient to decide or take the necessary safeguards when proceeding with a surgical intervention in the middle-aged population.

02

Conditions studied

  • Spatial Memory Disorder

Browse trials for

03

In context

Memory Disorders

373 studies on the registry are indexed under Memory Disorders; 67 are open to participants now.

This study's planned enrollment of 22 is below the median of 187 across 62 observational studies indexed under Memory Disorders.

Browse Memory Disorders studies →

Lead sponsor

University of Chile is the lead sponsor of 194 studies on the registry; 38 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 50 Years
Sexes eligible
All
Sampling method
Non-probability sample

Study population

Adult patients bewteen 30 and 50 years old who will undergo to an elective laparoscopic surgery of cholecystectomy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Candidate for elective laparoscopic surgery of cholecystectomy.
  • Age 30 to 50 years.

Exclusion criteria

Exclusion Criteria:

  • Visual or hearing difficulties.
  • Malignant hyperthermia.
  • Being treated with centrally acting drugs, such as anxiolytics, antidepressants, antipsychotics, anticonvulsants, anticholinergics, and first-generation antihistamines.
  • Present a disorder of the sphere of neuropsychiatry
  • Substance abuse disorder.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
22 participants (estimated)
Target follow-up
30 Days
Patient registry
Yes
Biospecimen retention
Samples without dna

Groups and cohorts

  • Adults 30-50 years

    Procedure: Surgery/general anesthesia

Interventions

  • ProcedureSurgery/general anesthesia

    Adult patients between the ages of 30 and 50 who are to undergo elective surgery under general anesthesia will have their spatial memory tested and interleukin 1beta and alpha tumor necrosis measured before and after surgery.

06

What researchers measure

Primary outcomes

  1. Virtual spatial memory

    Time to reach the goal

    Time frame: 1th day after surgery

Secondary outcomes

  1. Interleukin-1beta

    Interleukin-1beta plasma concentration

    Time frame: 1st day after surgery

  2. Interleukin-1beta

    Interleukin-1beta plasma concentration

    Time frame: 7th day after surgery

  3. Interleukin-1beta

    Interleukin-1beta plasma concentration

    Time frame: 30th day after surgery

  4. Tumor necrosis factor alpha

    Tumor necrosis factor alpha plasma concentration

    Time frame: 1st day after surgery

  5. Tumor necrosis factor alpha

    Tumor necrosis factor alpha plasma concentration

    Time frame: 7th day after surgery

  6. Tumor necrosis factor alpha

    Tumor necrosis factor alpha plasma concentration

    Time frame: 30th day after surgery

  7. Virtual spatial memory

    Time to reach the goal

    Time frame: 7st day after surgery

  8. Virtual spatial memory

    Time to reach the goal

    Time frame: 30th day after surgery

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Nov 2025, 27 months after the start.

Of 23 observational studies under Memory Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 208. This study's planned 27 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 7, 2023
First posted
Aug 15, 2023
StartActual
Aug 14, 2023
Primary completionEst.
Nov 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Nov 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05991817
Responsible party
Sponsor
First posted
Aug 15, 2023
Start date
Aug 14, 2023
Primary completion
Nov 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Nov 20, 2025

Study contacts

Antonello Penna, MD, PhD
Contact
apenna@uchile.cl
+56956766623
Khaleed Etchegaray
Contact
khaleed.etchegaray@gmail.com
+56973310929
Khaleed Etchegaray
principal investigator · University of Chile
Jamileth More, PhD
study director · University of Chile
Antonello Penna, MD, PhD
study director · University of Chile

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion